Skylar is an associate editor for The American Journal of Managed Care® (AJMC®) and The Center for Biosimilars®, and joined AJMC® in 2020. She is responsible for covering all aspects of the ever-changing global biosimilar industry and produces content that is accessible and informative for all health care stakeholders.
She has a BA in journalism and media studies from Rutgers University. You can connect with Skylar on LinkedIn.
AMCP Nexus 2023 to Showcase Regulatory, Policy Updates and Evolving Managed Care Strategies
October 11th 2023The annual fall meeting of AMCP Nexus 2023 will feature discussions on the evolving managed care landscape, including the impact of the Inflation Reduction Act, the specialty pharmaceutical pipeline, insight into the growing use of diabetes drugs for weight loss, and more.
Read More
First Tocilizumab Biosimilar Approved in the United States
October 5th 2023The FDA has approved Tofidence, the first tocilizumab biosimilar in the United States, which will be used to treat rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis.
Read More
New Blood Test Can Diagnose GLUT1 Deficiency Syndrome
September 26th 2023A new study confirmed the validity of a blood test that can diagnose patients with GLUT1 deficiency syndrome, a treatable neurometabolic disease that causes a wide range of neurologic symptoms in children and adults, including seizures.
Read More
AAM Report: Generics and Biosimilars Generate $408 Billion in 2022
September 15th 2023A report from the Association for Accessible Medicines (AAM) highlighted the value of biosimilars and generics, revealing that lower-cost versions of originator products accumulated $408 billion for the US health care system in 2022.
Read More
Stelara and Enbrel Chosen for IRA Price Negotiation
August 31st 2023The Biden administration has released the first 10 drugs subject to price negotiation with Medicare under the Inflation Reduction Act (IRA), and among those chosen were Stelara (ustekinumab) and Enbrel (etanercept), both of which will face biosimilar competition within the next decade.
Read More
Dr Joseph Mikhael on Strategies to Increase Diversity in Multiple Myeloma Trials
August 28th 2023Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, highlights several potential strategies to address the historic lack of diversity in multiple myeloma clinical trial populations.
Read More
Dr Jennifer Brown Discusses Zanubrutinib Uptake in CLL, SLL
August 23rd 2023Jennifer Brown, MD, PhD, director of the Chronic Lymphocytic Leukemia Center at Dana-Farber Cancer Institute, discussed the uptake of zanubrutinib for the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL).
Read More
AAM White Paper Offers Causes and Solutions to the US Generic Drug Shortage
July 30th 2023A white paper crafted by the Association for Accessible Medicines (AAM) outlined that main causes of generic drug shortages and recommended several actions for stakeholders to remedy current shortages and prevent future ones.
Read More
Patients With CML Feel Shared Decision-Making Is Lacking, Want More Focus on QOL
July 25th 2023Data from the Survey of Unmet Needs in Chronic Myeloid Leukemia (CML SUN) trial show that quality of life (QOL) and shared decision-making are priorities for patients, said Fabian Lang, MD, of Goethe University Hospital in Frankfurt, Germany.
Read More
Dr Joseph Mikhael on Strategies to Increase CAR T-Cell Therapy Access
July 22nd 2023Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed the manufacturing challenges sometimes seen with chimeric antigen receptor (CAR) T-cell therapies and strategies being implemented to improve access for historically underserved patients.
Read More
Dr Franco Locatelli Discusses the Treatment of Patients with cGvHD
July 21st 2023Franco Locatelli, MD, PhD, head of the Department of Pediatric Hematology and Oncology at IRCCS Bambino Gesu Children’s Hospital in Rome, discusses the treatment of both adult and pediatric patients with chronic graft versus host disease (cGvHD).
Read More
Despite Steep Discounts, Humira Biosimilars Are Priced More Than Original Originator Price
July 21st 2023Even at a steep discount, the list prices of new adalimumab biosimilars are significantly higher than the original price of the originator product (Humira), highlighting how dramatically its list price has risen over the years.
Read More
Dr Fabian Lang on the Importance of Patient Involvement in CML Treatment Decisions
July 7th 2023In a disease such as chronic myeloid leukemia (CML), shared treatment decision-making between providers and patients is key, said Fabian Lang, MD, of Goethe University Hospital in Frankfurt, Germany.
Read More
Dr Courtney DiNardo Sheds Light on FDA Fast Track Designation and Its Impact on Drug Development
June 11th 2023Courtney DiNardo, MD, MSCE, the lead author on a study presented at EHA 2023 evaluating a new therapy for chronic myelomonocytic leukemia and acute myeloid leukemia, discusses the FDA Fast Track Designation for IO-202 and strategies for raising awareness and improving diversity in clinical trials.
Read More
Dr Yael Cohen Explains the Barriers to Accessing Triplet Combination Therapies for MM
June 11th 2023More data is emerging on the efficacy of several triplet therapies to treat single-class refractory multiple myeloma (MM), potentially giving patients more therapy options than ever before, according to Tel-Aviv Sourasky Medical Center's Yael Cohen, MD, at the European Hematology Association 2023 Congress.
Read More
Dr Wojciech Jurczak Gives Insight Into the Phase 2 L-MIND Trial in DLBCL
June 11th 2023Wojciech Jurczak, MD, PhD, lead researcher on the L-MIND study evaluating a new treatment combination in diffuse large B-cell lymphoma (DLBCL), gave an overview of the trial results that were presented at the European Hematology Association 2023 Congress.
Read More
Dr Jennifer Brown Speaks on Use of BTK, BCL-2 Inhibitors in CLL Treatment
June 10th 2023Jennifer Brown, MD, PhD, Dana-Farber Cancer Institute, shared her thoughts on the current research regarding Bruton tyrosine kinase (BTK) and B-cell lymphoma 2 (BCL-2) inhibitors in chronic lymphocytic leukemia (CLL) and what providers should keep in mind before prescribing them.
Read More
Dr Hans Lee Discusses Infection Risks for Bispecific Therapies for Patients With MM
June 10th 2023MD Anderson Cancer Center's Hans Lee, MD, shared considerations for possible infection risk associated with bispecific therapies used to treat relapsed/refractory multiple myeloma (MM) at the European Hematology Association 2023 Congress
Read More
Mark Cuban’s Online Pharmacy Partners With Coherus Biosciences for Humira Biosimilar
June 8th 2023The Mark Cuban Cost Plus Drug Company, an online pharmacy dedicated to increasing access to lower-cost prescriptions, is partnering with Coherus Biosciences to distribute Yusimry, a biosimilar referencing Humira. It’s the first time the pharmacy has added a biosimilar to its list of drugs.
Read More